Trastuzumab and T-DXd are effective in HER2-positive gastric and GEJ cancers, moving towards earlier intervention stages. A meta-analysis of T-DXd showed significant efficacy and manageable safety in ...

A regulatory decision is expected during the first quarter of 2026. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for ...

A regulatory decision is expected during the first quarter of 2025. The Food and Drug Administration has accepted for Priority Review the supplemental Biologics License Application (sBLA) for ...

A study demonstrated the efficacy of trastuzumab deruxtecan (Enhertu) in patients with HER2-positive advanced or metastatic breast cancer, including those with brain metastases. Senior author Nancy ...

Trastuzumab deruxtecan is approved for HR-positive, HER2-low/ultralow metastatic breast cancer post-endocrine therapy, based on DESTINY-Breast06 trial results. The trial showed a 36% reduction in ...

Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine ...

HER2 and ABCC1 are identified as significant transcriptomic predictors of overall survival in patients treated with T-DXd. A large-scale analysis reveals novel predictors of survival and resistance ...

Based on DESTINY-Breast06 Phase III trial results which showed ENHERTU demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year Approval brings ...

A randomized, double-blind, three-arm, parallel group, phase 1 study to assess the pharmacokinetics, safety, and tolerability of PERT-IJS following a single dose of 420 mg intravenous infusion ...

Please provide your email address to receive an email when new articles are posted on . Trastuzumab deruxtecan showed substantial and durable overall and intracranial clinical activity in patients ...

The antibody-drug conjugate trastuzumab deruxtecan (T-DXd, Enhertu) proved active in a phase II study of advanced HER2-positive colorectal cancer (CRC). Almost 40% of patients treated with the ...